Resistance to gemcitabine is related to increased levels of activated Akt, and the upregulation of phosphorylated Akt enhances productive infection by myxoma virus, suggesting that myxoma virus may be a potential alternative therapy for pancreatic cancer, especially for those resistant to gemcitabine 120-122. The gene discussed is AKT1; the disease is pancreatic neoplasm.